+ Watch GALE
on My Watchlist
Neuvax, highly undervalued due to scandal, still solid company with an excellent pipeline.
Great new anti-cancer developments.
highly undervalued, huge potential, has 2 drugs approved
Great chances of being revenue positive towards the end of the year thanks to drug Abstral. Huge market potential for breast cancer drug NueVax (if passed by FDA. it has great chances). Positive ratings from many analysts. Oh, and it’s undervalued due to recently ended bear raid. All and all, great stock and price with multi bagger potential for 2014. check it out.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions